Physician profile
Iqbal Singh
NPI 1982667960
$5,783.24
in general payments reported to CMS, 2019-2025
36 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $721 · 2021: $1,107 · 2022: $389 · 2023: $802 · 2024: $1,114 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.09 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Ucb, INC. | $514.00 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Sunovion Pharmaceuticals INC. | $439.87 | 2019-2022 | |
| Biogen, INC. | $363.39 | 2020-2023 | Vumerity |
| Sk Life Science, INC. | $345.19 | 2024-2025 | Xcopri |
| Argenx US, INC. | $327.63 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sumitomo Pharma America, INC. | $313.75 | 2023-2024 | Aptiom |
| Teva Pharmaceuticals USA, INC. | $300.24 | 2019-2022 | |
| Neurelis, INC. | $298.32 | 2020-2025 | Valtoco |
| Eisai INC. | $247.30 | 2019-2023 | |
| Lundbeck LLC | $202.45 | 2021-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $196.58 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $194.41 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $186.98 | 2025 | Ponvory |
| Acadia Pharmaceuticals INC | $170.55 | 2019-2025 | Nuplazid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $132.90 | 2022-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $131.93 | 2020 | |
| Lilly USA, LLC | $96.50 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $61.07 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $60.12 | 2023-2024 | Fycompa |
| Emd Serono, INC. | $56.76 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $54.33 | 2019-2021 | |
| Amgen INC. | $46.23 | 2020-2021 | |
| Pfizer INC. | $44.06 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $42.87 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $32.27 | 2022 | |
| Assertio Therapeutics, INC. | $29.66 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.79 | 2021 | |
| Harmony Biosciences LLC | $24.53 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.95 | 2024 | |
| Supernus Pharmaceuticals, INC. | $22.78 | 2020-2021 | |
| Nevro Corp. | $20.97 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.96 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.54 | 2024 | Nuedexta |
| Arbor Pharmaceuticals, INC. | $15.17 | 2021 | |
| Merck Sharp & Dohme LLC | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iqbal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.